Learn why antibiotics only modestly outperform placebo in adult sinusitis trials and when guidelines support watchful waiting vs treatment.
Antibiotics for uncomplicated adult sinusitis provide only a modest benefit on average, so boards emphasize selective prescribing rather than routine treatment.
A 20-year-old man presents to you with what he calls "pain in my cheeks" following an upper respiratory infection that lasted 5 days. He does not appear ill. His temperature is 37.5C and he has mucopurulent discharge from both nares. You do not observe any nasal obstruction. The maxillary sinuses are moderately tender to palpation. The ear canals and drums are normal, as is the oropharynx. He has taken no medication.
Among placebo-controlled, randomized clinical trials of antibiotic therapy in adults with presumed acute bacterial sinusitis, which of the following statements is correct?
Answer Options:
This item is frequently missed because test-takers conflate two different truths: (1) antibiotics can beat placebo in trials (a modest average effect), and (2) guidelines still recommend against routine antibiotics for uncomplicated, early presentations because spontaneous improvement is common and adverse effects are increased. AAO-HNSF (2015) supports watchful waiting for uncomplicated ABRS when follow-up is assured, reflecting that the average benefit is small and not worth universal exposure.
Also note the stem’s clinical timing (5 days after URI onset, afebrile, not ill-appearing) is more consistent with viral rhinosinusitis than ABRS by standard diagnostic heuristics (persistent ≥10 days, severe onset with high fever/purulence ≥3–4 days, or “double-worsening”). Boards often use this mismatch to see whether you can separate evidence of marginal efficacy from appropriate indications.
| Option | What It Tests / Implies | Why It’s Wrong Here |
|---|---|---|
| Most studies (>80%) showed that antibiotics were superior to placebo. | Assumes antibiotics are overwhelmingly beneficial across trials | Overstates effect size/consistency; guideline-era evidence supports only modest average benefit, not “>80% of studies.” |
| The majority of studies (> 50%) showed that antibiotics were superior to placebo. | Recognizes a modest but real signal favoring antibiotics in trial literature | Best fit to the evidence base used in guideline discussions (small improvement vs placebo), while still compatible with selective-use recommendations (AAO-HNSF 2015). |
| Few studies (<20%) showed that antibiotics were superior to placebo. | Assumes antibiotics rarely help | Contradicts meta-analytic signal showing some benefit (though small absolute difference). |
| Antibiotics reduced the number of complications of acute sinusitis. | Assumes antibiotics prevent serious sinusitis complications | Not established for uncomplicated adult cases; complications are rare and observational data do not show clear reduction attributable to routine antibiotics. |
Even when antibiotics show statistical superiority to placebo in ABRS trials, guidelines still favor watchful waiting for uncomplicated cases because the absolute benefit is small and harms are real (AAO-HNSF 2015).
The stem nudges you toward “treat sinusitis,” but the question actually asks about the direction of evidence in placebo-controlled trials—a trap for learners who answer from guideline heuristics alone. The boards like this separation: a treatment can be modestly efficacious yet still inappropriate to give routinely.
A 34-year-old has nasal congestion, purulent nasal discharge, and facial pressure for 11 days without improvement. Afebrile, stable vitals, reliable follow-up. Best next step?
A 28-year-old improves after a viral URI, then worsens on day 7 with new fever 39°C and purulent discharge. Best interpretation?
In adult ABRS RCTs comparing antibiotics vs placebo, the most consistent finding is:
A 45-year-old with suspected sinusitis has severe unilateral periorbital edema, pain with eye movements, and decreased visual acuity. Next step?
A 52-year-old meets criteria for ABRS with severe symptoms and chooses antibiotics. No allergy. Best empiric choice?
Compare management for (1) 5 days of post-URI facial pressure with purulence vs (2) 12 days of persistent symptoms vs (3) “double-worsening”—how do your diagnostic certainty and antibiotic threshold change?
Q1: Why do guidelines allow watchful waiting if antibiotics can outperform placebo?
A: Because the absolute benefit is small, many patients improve without antibiotics, and adverse effects are more common—boards expect stewardship-consistent decision-making (AAO-HNSF 2015).
Q2: What symptom patterns most strongly support ABRS on exams?
A: Persistent symptoms ≥10 days, severe onset (high fever with purulence for several days), or double-worsening; these patterns are repeatedly tested.
Q3: Do antibiotics prevent serious sinusitis complications?
A: Not reliably in uncomplicated adult cases; complications are rare, and prevention has not been established as a reason for routine antibiotics.
Q4: What’s the first-line antibiotic when you do treat adult ABRS?
A: Amoxicillin-clavulanate is the guideline-preferred empiric choice in many adult cases (AAO-HNSF 2015).
This question appears in Med-Challenger Internal Medicine Review with CME
Try for free and save. Ace your exams and meet your CME/MOC requirements for just $35 a month!
No matter your program, no matter the size, Med-Challenger for Groups and Institutions can better prepare your program or group, fulfill industry requirements, and increase test scores.
For personal medical education that includes board's prep, MOC, and CME requirements, Med-Challenger has you covered in Family Medicine, Emergency Medicine, Internal Medicine, Pediatrics, Pediatric Emergency Medicine, OBGYN, Physician Assistants, and Nurse Practitioners.
Learn why glucose oxidase strips can read falsely low in newborns, when to confirm with lab plasma glucose, and common board-style traps.
Why EMTALA transfer rules trip up test-takers. Learn the two lawful pathways for unstable transfers and the elements of an appropriate transfer.
Understand ABFM pass rates, why first-time outcomes differ, and what trends really reveal about exam difficulty and your likelihood of passing.